Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...

Teva Pharmaceutical (NYSE:TEVA) and Alvotech (NASDAQ:ALVO) have launched their biosimilar targeting Johnson & Johnson’s (NYSE:JNJ) blockbuster arthritis therapy Stelara (ustekinumab) in the U.S. weeks ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to ... UCCD study in patients with moderate-to-severe ulcerative colitis (UC) and Crohn's disease suggest a "best ...

We make things happen." On the branded drug Duvakitug, which Teva is developing with Sanofi, for the treatment of ulcerative colitis and Crohn's disease, and which surprised in December with strong ...

In patients with ulcerative colitis, vedolizumab outperformed infliximab as a second-line therapy following failure of ...

According to the National Institutes of Health, between 600,000 and 900,000 Americans have ulcerative colitis, a chronic ...

Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). The product is indicated for the ...

New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different dosesNew endpoints presented include findings on clin ...

The human gut is home to trillions of bacteria that play vital roles in digestion, immunity, and overall health. When this ...

ulcerative colitis, pediatric plaque psoriasis and pediatric psoriatic arthritis. This is the second biosimilar now available in the U.S. market under the Teva and Alvotech strategic partnership.

and the treatment of adult patients with moderately to severely active Crohn’s disease and ulcerative colitis PARSIPPANY, N.J. and REYKJAVÍK, Iceland, Feb. 21, 2025 (GLOBE NEWSWIRE) — Teva ...